All In Biotech

Drug Trial Radar · NCT04603001

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Nov 19, 2020

Primary completion

Jul 3, 2023

Study completion May 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

Conditions

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)
  • Myeloproliferative Neoplasms (MPNs)

Interventions

  • LY3410738Drug

    Oral LY3410738

  • VenetoclaxDrug

    Oral venetoclax

  • AzacitidineDrug

    Subcutaneous or intravenous azacitidine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)Time frame: Up to 30 months
  2. To assess the activity of LY3410738 as measured by the overall response rate (ORR) per the Investigator assessmentTime frame: Up to 30 months

Locations

37 sites in 12 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • University of California, Davis - Health Systems

    Sacramento, California

  • H Lee Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Hospital

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • BC Cancer Vancouver

    Vancouver, British Columbia, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)

    Helsinki, Finland

  • Institut Paoli-Calmettes

    Marseille, France

  • Hopital Saint Louis

    Paris, France

  • Centre hospitalier universitaire de Haut Leveque

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Institut Claudius Regaud

    Toulouse, France

  • Medizinische Hochschule Hanover

    Hanover, Lower Saxony, Germany

  • Rambam Medical Center

    Haifa, Israel

  • National University Cancer Institute

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], South Korea

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], South Korea

  • Clinico Y Provincial Barcelona

    Barcelona, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario La Fe de Valencia

    Valencia, Spain

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.